Moderna and Merck's Personalized mRNA Melanoma Vaccine Meets Phase 3 Endpoints
On Wednesday, Moderna and Merck revealed that their personalized mRNA cancer vaccine, when used alongside Merck's immunotherapy Keytruda, met its primary and a significant secondary endpoint in a crucial Phase 3 trial. This study involved patients who had undergone surgery for high-risk melanoma. This achievement marks the first successful Phase 3 outcome for both individualized neoantigen therapies and mRNA-based cancer treatments. The announcement was made collaboratively by the companies, emphasizing the vaccine's promising role in melanoma treatment.
Key facts
- Moderna and Merck announced results on a Wednesday.
- The vaccine is personalized and mRNA-based.
- It was tested in combination with Keytruda.
- The Phase 3 trial met its primary and a key secondary endpoint.
- The trial involved patients with surgically removed high-risk melanoma.
- This is the first positive Phase 3 result for an individualized neoantigen therapy.
- It is also the first positive Phase 3 result for any mRNA-based cancer treatment.
Entities
Institutions
- Moderna
- Merck
- Keytruda
Sources
- Quartz —